Table 1.
Baseline Demographics
| Control | PsA | Mild Psoriasis | Severe Psoriasis | RA | ||
|---|---|---|---|---|---|---|
| N | 821,834 | 9,788 | 149,809 | 8,514 | 39,306 | |
| Age | Mean (SD) |
50.18 (17.47) | 49.74 (14.09) | 46.67 (17.43) | 49.29 (15.18) | 58.71 (15.33) |
| Female Sex | N (%) | 469,431 (57.12%) |
5,029 (51.38%) | 79,961 (53.38%) | 4,498 (52.83%) | 27,198 (69.20%) |
| Cohort Time* | Mean (SD) |
6.75 (4.87) | 6.17 (4.67) | 6.37 (4.80) | 5.50 (4.19) | 6.29 (4.67) |
| Visits in One Year before start |
Mean (SD) |
4.86 (6.45) | 8.03 (8.81) | 6.22 (6.72) | 10.54 (10.13) | 10.02 (9.61) |
| Cancer** | N (%) | 121,488 (14.78%) |
1,218 (12.44%) | 20,546 (13.71%) | 1,264 (14.85%) | 6,092 (15.50%) |
| Chronic Kidney Disease |
N (%) | 17,335 (2.11%) | 188 (1.92%) | 2,426 (1.62%) | 249 (2.92%) | 1,332 (3.39%) |
| Atrial Fibrillation |
N (%) | 16,923 (2.06%) | 160 (1.63%) | 2,425 (1.62%) | 142 (1.67%) | 1,263 (3.21%) |
| Diabetes | N (%) | 49,554 (6.03%) | 743 (7.59%) | 8,091 (5.40%) | 768 (9.02%) | 3,204 (8.15%) |
| Cardiovascular Disease |
N (%) | 48,647 (5.92%) | 458 (4.68%) | 7,640 (5.10%) | 479 (5.63%) | 3,712 (9.44%) |
| COPD | N (%) | 17,585 (2.14%) | 207 (2.11%) | 3,262 (2.18%) | 233 (2.74%) | 1,654 (4.21%) |
| Liver disease | N (%) | 9,653 (1.17%) | 182 (1.86%) | 1,947 (1.30%) | 163 (1.91%) | 594 (1.51%) |
| Dementia | N (%) | 3,963 (0.48%) | 32 (0.33%) | 788 (0.53%) | 30 (0.35%) | 357 (0.91%) |
| Stroke | N (%) | 21,827 (2.66%) | 205 (2.09%) | 3,450 (2.30%) | 212 (2.49%) | 1,613 (4.10%) |
| Anti-depressant use |
N (%) | 178,630 (21.74%) |
2,861 (29.23%) | 33,252 (22.20%) | 2,834 (33.29%) | 11,805 (30.03%) |
| Anti-epileptic use |
N (%) | 25,338 (3.08%) | 398 (4.07%) | 4,774 (3.19%) | 424 (4.98%) | 1,877 (4.78%) |
| Oral corticosteroids |
N (%) | 77,521 (9.43%) | 1,645 (16.81%) | 12,811 (8.55%) | 1,819 (21.36%) | 11,532 (29.34%) |
| PPI use | N (%) | 125,493 (15.27%) |
3,021 (30.86%) | 22,615 (15.10%) | 2,666 (31.31%) | 13,408 (34.11%) |
| Hormone therapy*** |
N (%) | 252,829 (30.76%) |
2,643 (27.00%) | 40,218 (26.85%) | 2,521 (29.61%) | 11,158 (28.39%) |
| Smoking | Never/ Former (N, %) |
561,085 (68.27%) |
6,966 (71.17%) | 92,044 (61.44%) | 5,658 (66.46%) | 26,497 (67.41%) |
| Current (N, %) |
170,562 (20.75%) |
2,011 (20.55%) | 41,751 (27.87%) | 2,322 (27.27%) | 8,676 (22.07%) | |
|
Missing (N, %) |
90,187 (10.97%) | 811 (8.29%) | 16,041 (10.69%) | 534 (6.27%) | 4,133 (10.51%) | |
| Alcohol Use | Never (N, %) |
96,244 (11.72%) | 1,150 (11.75%) | 16,023 (10.70%) | 973 (11.43%) | 6,503 (16.54%) |
| Some (N, %) |
519,079 (63.16%) |
6,462 (66.02%) | 97,034 (64.77%) | 5,600 (65.77%) | 23,137 (58.86%) |
|
| Heavy (N, %) |
31,735 (3.86%) | 477 (4.87%) | 5,501 (3.67%) | 552 (6.48%) | 2,167 (5.51%) | |
|
Missing (N, %) |
174,676 (21.25%) |
1,699 (17.36%) | 31,251 (20.86%) | 1,389 (16.31%) | 7,499 (19.08%) | |
| BMI |
Mean (SD) |
26.39 (5.46) | 28.03 (5.86) | 26.65 (5.60) | 28.08 (6.11) | 26.69 (5.55) |
|
Missing (N, %) |
168,709 (20.53%) |
1,659 (16.95%) | 30,833 (20.58%) | 1,327 (15.59%) | 7,446 (18.94%) | |
*
Time from index date to end date
**
Cancer includes hematologic malignancy and solid tumor malignancies
***
Hormone therapy refers to the use of oral contraceptives as well as hormone replacement therapy
Abbreviations: PPI = proton pump inhibitor; BMI = Body Mass Index